EGFR and hepatocellular carcinoma: Assuming that EGFR drives NASH-to-HCC progression, and that HCC prevention requires the use of non-toxic agents, especially in patients with particularly low liver function, we focused on HCC development and tested the preventative ability of HNK, a naturally occurring compound known to have anti-inflammatory and anti-oxidant activities [14].